Lista de obras -

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

artículo científico publicado en 2008

Additive influences of acute early life stress and sex on vulnerability for aversion-resistant alcohol drinking

artículo científico publicado en 2019

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

artículo científico publicado en 2008

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

artículo científico publicado en 2007

Chemotherapy and novel therapeutic approaches in malignant glioma

artículo científico publicado en 2005

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma

artículo científico publicado en 2008

Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

artículo científico publicado en 2007

Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma

artículo científico publicado en 2008

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results

artículo científico publicado en 2006

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

artículo científico publicado en 2006

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma

artículo científico publicado en 2004

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

artículo científico publicado en 2009

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma

artículo científico publicado en 2004

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

artículo científico publicado en 2005

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

artículo científico publicado en 2009

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

artículo científico publicado en 2005

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme

artículo científico publicado en 2006

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

artículo científico publicado en 2007

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

artículo científico publicado en 2005

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme

artículo científico publicado en 2009

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

artículo científico publicado en 2007

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

artículo científico publicado en 2002

Phase II trial of gefitinib in recurrent glioblastoma

artículo científico publicado en 2003

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas

artículo científico publicado en 2002

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

artículo científico publicado en 2009

Phase II trial of temozolomide in patients with progressive low-grade glioma

artículo científico publicado en 2003

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

artículo científico publicado en 2009

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

artículo científico publicado en 2005

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

artículo científico publicado en 2003

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma

artículo científico publicado en 2006

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma

artículo científico publicado en 2008

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

artículo científico publicado en 2006

Selective enhancement of fear learning and resistance to extinction in a mouse model of acute early life trauma

scientific article published on 15 December 2020

Survival analysis of presumptive prognostic markers among oligodendrogliomas.

artículo científico publicado en 2005

Temozolomide in children with progressive low-grade glioma

artículo científico publicado en 2007

Lista de obras de

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

Additive influences of acute early life stress and sex on vulnerability for aversion-resistant alcohol drinking

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

Chemotherapy and novel therapeutic approaches in malignant glioma

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma

Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

Phase II trial of gefitinib in recurrent glioblastoma

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

Phase II trial of temozolomide in patients with progressive low-grade glioma

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

Selective enhancement of fear learning and resistance to extinction in a mouse model of acute early life trauma

Survival analysis of presumptive prognostic markers among oligodendrogliomas.

Temozolomide in children with progressive low-grade glioma